{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:40:36Z","timestamp":1753890036938,"version":"3.41.2"},"reference-count":0,"publisher":"American Diabetes Association","issue":"Supplement_1","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"abstract":"<jats:p>Introduction: Subclinical hypothyroidism (SCH) seems to be associated with increase in cardiovascular risk factors and insulin resistance. The effect of the treatment of SCH with L-thyroxine on cardiovascular profile is not yet clear.<\/jats:p>\n               <jats:p>Methods: We evaluated the effects of L-thyroxine therapy in 120 patients (mean age 45.7 \u00b1 12.2 years, 80 women) with SCH due to autoimmune thyroiditis that had no prior treatment for thyroid or cardiovascular disease. The treatment was titrated to TSH levels between 0.4 and 4.0mIU\/L. The laboratory data obtained, before and at least 6 months after thyroid function normalization, included thyroid function, antithyroid antibodies, lipid profile, and HOMA-IR (Homeostasis Model Assessment for insulin resistance), HISI (Hepatic Insulin Sensitivity Index), and IGI (Insulinogenic Index). Statistical analysis was performed with Mann-Whitney test, and Spearman\u2019s correlation coefficient.<\/jats:p>\n               <jats:p>Results: After treatment L-thyroxine, we observed a significant decrease of TSH (6.43\u00b10.53 to 1.23\u00b10.42 mIU\/L, p=0.03) and a significant increase of fT4 (0.74\u00b10.12 to 1.25\u00b10.14 ng\/mL, p&amp;lt;0.05). We also observed a decrease of LDL (116.1\u00b134.2 to 91.2\u00b116.3 mg\/dL, p&amp;lt;0.01) and Lp(a) (32.0 \u00b119.1 mg\/dL to 21.4\u00b118.1 mg\/dl, p&amp;lt;0,01). HDL and Apo A1 increased significantly after treatment (45.2\u00b115.2 to 58.5\u00b118.1 mg\/dL, p &amp;lt;0.01; 124.5\u00b143.3 vs. 136.5\u00b156.4 mg\/dL, p&amp;lt;0.01, respectively). Treatment with L-thyroxine significantly reduced HOMA-IR (0.24\u00b10.17 to 0.17\u00b10.10, p=0.03) and HISI (334.9\u00b192.9 to 703.8\u00b197.1, p=0.02). At baseline, TSH was positively correlated with total cholesterol (r=0.38, p=0.01), LDL (r=0.38, p=0.01), TG (r=0.28, p=0.01) and IGI (r=0.22, p=0.05). FT3 was negatively correlated with Lp(a) (r =-0.41, p=0.04).<\/jats:p>\n               <jats:p>Conclusions: The treatment of SCH in patients with autoimmune thyroiditis is associated with a significant improvement of insulin resistance and cardiovascular risk.<\/jats:p>\n               <jats:sec>\n                  <jats:title>Disclosure<\/jats:title>\n                  <jats:p>C. Neves: None. S.C. Oliveira: None. J. Neves: None. M.G. Pereira: None. O. Sokhatska: None. A. Oliveira: None. J. Medina: None. L. Delgado: None. D.M. Carvalho: None.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/db18-1975-p","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T18:57:33Z","timestamp":1529693853000},"update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":1,"title":["Improvement of Insulin Resistance and Cardiovascular Risk Factors with Treatment of Subclinical Hypothyroidism in Patients with Autoimmune Thyroiditis"],"prefix":"10.2337","volume":"67","author":[{"given":"CELESTINO","family":"NEVES","sequence":"first","affiliation":[{"name":"Porto, Portugal"}]},{"given":"SOFIA C.","family":"OLIVEIRA","sequence":"additional","affiliation":[{"name":"Porto, Portugal"}]},{"given":"JO\u00c3O S\u00c9R","family":"NEVES","sequence":"additional","affiliation":[{"name":"Porto, Portugal"}]},{"given":"MIGUEL G.","family":"PEREIRA","sequence":"additional","affiliation":[{"name":"Porto, Portugal"}]},{"given":"OKSANA","family":"SOKHATSKA","sequence":"additional","affiliation":[{"name":"Porto, Portugal"}]},{"given":"ANA","family":"OLIVEIRA","sequence":"additional","affiliation":[{"name":"Porto, Portugal"}]},{"given":"JOS\u00c9 LUIZ","family":"MEDINA","sequence":"additional","affiliation":[{"name":"Porto, Portugal"}]},{"given":"LUIS","family":"DELGADO","sequence":"additional","affiliation":[{"name":"Porto, Portugal"}]},{"given":"DAVIDE M.","family":"CARVALHO","sequence":"additional","affiliation":[{"name":"Porto, Portugal"}]}],"member":"1167","container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/67\/Supplement_1\/1975-P\/55512\/Improvement-of-Insulin-Resistance-and","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/67\/Supplement_1\/1975-P\/55512\/Improvement-of-Insulin-Resistance-and","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T09:33:41Z","timestamp":1647164021000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/67\/Supplement_1\/1975-P\/55512\/Improvement-of-Insulin-Resistance-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":0,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db18-1975-p","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"type":"print","value":"0012-1797"},{"type":"electronic","value":"1939-327X"}],"subject":[],"published":{"date-parts":[[2018,7,1]]},"article-number":"1975-P"}}